AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright Life Sciences Conference, taking place virtually on March 9-10, 2021. The presentation will be available on-demand starting March 9 at 7:00 AM Eastern Time. Registered attendees can access the webcast through the conference platform or the investor relations section of AIM's website. Additionally, management will engage in one-on-one meetings with qualified investors attending the event.
Details
News Market Reaction – AIM
The recorded move for AIM in the trading session of this news was -7.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.
AIM’s presentation will be available on-demand to registered attendees via the conference platform beginning Tuesday, March 9, 2021, at 7:00 AM Eastern Time. The webcast will be accessible here, and the presentation will be available on the investor relations section of AIM's website at https://aimimmuno.com/events-presentations/. Management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.